A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention

Regulations by 2FIRSTS
Oct.16.2024
A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
FDA updates import alert on a product of Zhuhai Qisitech Co., Ltd., a subsidiary of Geekvape, for tobacco product violations.

Editor's Note:

After the publication of this article, some experts pointed out that Import Alert 98-06 is aimed at products rather than companies, that is, this time it targets the RAZ DC25000 ENDS products, not all products of Qisitech. 
For the sake of accuracy, this article has been specially updated.


 

Recently, the official website of the U.S. Food and Drug Administration (FDA) updated Import Alert 98-06. 2Firsts noticed that a product of Zhuhai Geekvape Technology Co., Ltd. (hereinafter referred to as "Geekvape"), was included in the latest import alert list.

A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
Information disclosed on the FDA website for Zhuhai Qisitech Co., Ltd. | Image source: FDA website

 

According to the FDA website, ZHUHAI QISITECH CO., LTD was listed in the "Import Alert 98-06" also known as the "Red List" updated on September 26th, titled "Detention Without Physical Examination of New Tobacco Products Without Required Marketing Authorization".

A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
ZhuHai QiSitech Co., Ltd.'s address matches the one published on the FDA official website. | Image source: Tianyancha

 

Comparison between information released by the FDA and information from Tianyancha shows that ZHUHAI QISITECH CO., LTD, also known as Zhuhai Qisi Manufacturing Co., Ltd., was established in 2021 and is a wholly-owned subsidiary of Shenzhen Geekvape Technology Co., Ltd. Geekvape is the brand owner of Geek Bar and Geek Vape, two of the most well-known e-cigarette brands in the United States, while Qisitech is one of the main contract manufacturers under Geekvape.

 

A Product of Geekvape's Subsidiary Zhuhai Qisitech Listed in FDA Import Alert, Facing Risk of Automatic Detention
Zhuhai Qisi Intelligent Manufacturing Co., Ltd. is a wholly-owned subsidiary of Geekvape Technology Co., Ltd. in Shenzhen | Image source: Tianyancha

 

According to the FDA official website, departments can detain tobacco products listed on the Red List of this Import Alert without needing to conduct physical examinations. If a company wants to remove their products from the list, they must provide information to the relevant agencies to demonstrate that they have addressed the issues leading to non-compliance.

 

According to the above provisions, Qisitech's exports of the mentioned product to the United States will be detained until they are removed from Import Alert 98-06 list.

 

Compliance expert Kurt informed 2Firsts that Import Alert 98-06 is a list of companies that have submitted PMTAs (Pre-Market Tobacco Product Applications). Meanwhile, Import Alert 98-07, as listed on the FDA website, is focused on companies that have submitted PMTA applications.

 

2Firsts will continue to monitor the development of the event and provide timely updates on related coverage.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives
Multi-agency crackdown targets vape and convenience stores across Wirral, seizing illegal cigarettes and non-compliant pods
Multi-agency crackdown targets vape and convenience stores across Wirral, seizing illegal cigarettes and non-compliant pods
A multi-agency, intelligence-led enforcement operation took place on January 27, 2026, targeting vape and convenience stores across Wirral, including West Kirby, to disrupt the supply of illegal tobacco and vaping products. Six premises were inspected, with approximately 10,500 illegal cigarettes seized along with vape pods that were not in original packaging or did not meet UK regulatory requirements.
Feb.05 by 2FIRSTS.ai
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.
Jan.21 by 2FIRSTS.ai
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
British American Tobacco (BAT) CEO Tadeu Marroco said the group will continue to invest in equipment and technology in Italy and expand capacity for next-generation tobacco products such as e-cigarettes and heated tobacco. BAT’s Trieste innovation hub is slated to receive a total investment of 500 million euros by 2027 and add 16 new production lines.
Feb.03 by 2FIRSTS.ai
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?
Feb.09 by Alan Zhao | 2Firsts Perspectives